Overview

Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:
10

Participant gender:
All

Summary

The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Minnesota - Clinical and Translational Science Institute

Treatments:

Bilirubin

Last Updated:

2017-09-13

Criteria

Inclusion Criteria:

- hepatocellular carcinoma (HCC)

- Direct or conjugated bilirubin < 3 mg/dl

- Total bilirubin > 3 mg/dl

- Willing and able to provide informed consent

- >18 years of age

Exclusion Criteria:

- Currently pregnant

- Patients who are surgical or ablation candidates as determined by multidisciplinary
hepatobiliary tumor conference.

- Arterial anatomy which would preclude selective transarterial chemoembolization

- Patients who have a INR or platelet count which are not correctable to <1.8 and
>35,000 respectively

- Patients with extrahepatic metastases

- Patients with portal vein invasion